TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12668651
Drug: Concurrent doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent doxorubicin and cyclophosphamide (AC) x 4 -> paclitaxel (T) x 4 every 2 weeks with filgrastim
Study: 12668651
Drug: Sequential doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential doxorubicin (A) x 4 -> paclitaxel (T) x 4 -> cyclophosphamide (C) x 4 every 3 weeks
Study: 12668651
Drug: Concurrent doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent doxorubicin and cyclophosphamide (AC) x 4 -> paclitaxel (T) x 4 every 3 weeks
Study: 9088999
Drug: Doxophylline 400
Normalized name: dyphylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxophylline 400 mg orally, 3 times daily
Study: 8251249
Drug: Pre-brush rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-brush rinse containing 0.03% triclosan and 0.125% copolymer, rinsed twice daily for 6 months.
Study: 8251249
Drug: Placebo pre-brush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pre-brush rinse, rinsed twice daily for 6 months.
Study: 29858688
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g Arg/day
Study: 29858688
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g Arg/day
Study: 29858688
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g Arg/day (placebo)
Study: 29953191
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 80 mg
Study: 29953191
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 81 mg
Study: 29953191
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 100 mg
Study: 2396603
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 325 mg
Study: 24261900
Drug: Penile traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile traction therapy (PTT) for 6 months
Study: 22909281
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone 0.3 mg/kg stat
Study: 22909281
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg/day for three days
Study: 18230747
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment for OSAHS
Study: 18230747
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of co-existent SDB
Study: 16686082
Drug: Antiretroviral Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral Medication Complexity Index (AMCI)
Study: 14974733
Drug: Difructose anhydride
Normalized name: maleic anhydride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difructose anhydride III (DFAIII) - 10 g in a 200 mL water solution
Study: 1437429
Drug: Neonates weighing
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonates weighing 750 to 999 g
Study: 1437429
Drug: Neonates weighing
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonates weighing 1000 to 1499 g
Study: 31824507
Drug: CMV glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV glycoprotein B (gB) vaccine
Study: 28795416
Drug: GPA 100
Normalized name: Oristar gpa
DrugBank: Ompenaclid (DB18819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPA 100 mg
Study: 28795416
Drug: Creatine 5
Normalized name: Creatine 5 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine 5 g
Study: 22045782
Drug: Dance-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance-based therapy (18 sessions of low-impact therapy)
Study: 3080286
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms, 5 doses over 24 hours)
Study: 3080286
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 doses over 24 hours)
Study: 25319870
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose vaccine
Study: 21744005
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplementation (AA, 51 g of amino acids and 40 g of carbohydrate)
Study: 21744005
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (PL, 91 g of carbohydrate)
Study: 17991698
Drug: Diazepam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (single oral dose)
Study: 17991698
Drug: Baclofen (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (single oral dose)
Study: 10366113
Drug: Bovine type
Normalized name: Bovine type I collagen
DrugBank: Bovine type I collagen (DB10771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine type II collagen (CII), 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months
Study: 16500579
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg)
Study: 19862609
Drug: Erythropoiesis stimulating
Normalized name: Erythropoiesis stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis stimulating agents (ESA) therapy
Study: 18067807
Drug: Propofol preconditioning
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol preconditioning (2 mg/kg pre-operatively and 5 mg.kg(‐1).h(‐1) intra-operatively)
Study: 18067807
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (midazolam 0.2 mg/kg pre‐ and 0.1 mg.kg(‐1).h(‐1) intra-operatively)
Study: 15187831
Drug: Crystalloid solutions
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solutions as initial volume expanders
Study: 11774289
Drug: L-cysteine-containing tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-cysteine-containing tablet
Study: 8643970
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of paclitaxel combined with cisplatin/etoposide plus radiation therapy
Study: 8643970
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of paclitaxel combined with carboplatin and extended-schedule etoposide
Study: 1860196
Drug: rt‐PA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA plus heparin
Study: 108738
Drug: Active marijuana
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active marijuana containing 6 mg delta 9‐THC
Study: 17585011
Drug: Bivalent P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent P. aeruginosa flagella vaccine
Study: 15317827
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) rHuEpo, single doses ranging from 10 to 500 IU/kg
Study: 15317827
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) rHuEpo, single doses ranging from 300 to 2400 IU/kg
Study: 15317827
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) rHuEpo, multiple doses of 150 IU/kg/3 times a week and 600 IU/kg/week
Study: 6131624
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg intravenously
Study: 19570236
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment as usual (TAU)
Study: 17166799
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (higher dose)
Study: 17166799
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (lower dose)
Study: 15132726
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous GnRH (5 microg every 90 min for 36 hours)
Study: 15132726
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose GnRH-agonist stimulation test (buserelin acetate, 10 microg/kg body weight)
Study: 9736567
Drug: 3 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day PMPA
Study: 9736567
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day PMPA
Study: 27740930
Drug: Overall glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall glucose metabolism alterations
Study: 25168278
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge)
Study: 23558602
Drug: Compound omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound omeprazole capsule (40 mg)
Study: 23558602
Drug: Delayed-release omeprazole
Normalized name: omeprazole Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release omeprazole (40 mg)
Study: 18715125
Drug: Water +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water + electrolyte solution
Study: 14644891
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy for at least 3 months
Study: 14644891
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy for more than 3 months
Study: 10730732
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg x kg(‐1) mivacurium
Study: 10730732
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg x kg(‐1) rocuronium
Study: 10730732
Drug: 0.08 mg
Normalized name: mestranol 0.08 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 mg kg(‐1) mivacurium plus 0.2 mg x kg(‐1) rocuronium
Study: 1729065
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion
Study: 8247075
Drug: Immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune globulin (2 g per kilogram of body weight)
Study: 27759623
Drug: 2-day antimicrobial
Normalized name: ANTIMICROBIALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day antimicrobial prophylaxis (antibiotic treatment on days 1 and 2)
Study: 27759623
Drug: 4-day antimicrobial
Normalized name: ANTIMICROBIALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day antimicrobial prophylaxis (antibiotic treatment on days 1 to 4)
Study: 26956650
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care (psychoeducation, guided Internet treatment, and face-to-face CBT)
Study: 25409776
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention (behavioural activation and medication management) delivered over eight to 10 weekly sessions by a case manager liaising with general practitioners.
Study: 20215619
Drug: efavirenz plus
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz plus continuation of current nucleoside reverse transcriptase inhibitors (efavirenz-B)
Study: 18566298
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (2 g/d)
Study: 18566298
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (2 g/d) plus lovastatin (40 mg/d)
Study: 12466335
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg androstenedione
Study: 14983409
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg androstenedione
Study: 11996927
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg androstenedione (control group)
Study: 8830642
Drug: Metamphocin (methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamphocin (methyl ether of amphotericin B) administered as drop-like intravenous injections in combination with local instillation of ketoconazole and dexamethasone.
Study: 1969678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 6‐methyl‐prednisolone and sulfasalazine (drug treatment)
Study: 376208
Drug: Fenoterol 0.25
Normalized name: fenoterol 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 0.25 mg
Study: 24646068
Drug: IV-ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-ibuprofen (10 mg·kg(‐1))
Study: 21674629
Drug: Optimized botanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized botanical combination containing policosanol, tomato extract, orally bioavailable grape procyanidins and Oenothera biennis oil
Study: 12225709
Drug: Late intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late intervention and stent to the LAD + medical therapy (open artery group)
Study: 12225709
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (closed artery group)
Study: 9606690
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (i.v.Ig) administered monthly at a dosage of 0.15‐0.20 g/kg for 2 years
Study: 7624465
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBT; n = 14)
Study: 7624465
Drug: Experiential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential group therapy program (ET; n = 12)
Study: 26257143
Drug: Concurrent low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent low-dose alcohol (0.065g/210L peak BrAC)
Study: 26257143
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid (OF) testing
Study: 24721888
Drug: Low-dose rapamycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rapamycin (LD)
Study: 24721888
Drug: Standard-dose rapamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose rapamycin (STD)
Study: 24721888
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (LD+STD)
Study: 22397390
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (music therapy and standard rehabilitation)
Study: 20134405
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) root 3 g
Study: 20134405
Drug: Ginsenoside fraction
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside fraction 3 g
Study: 20134405
Drug: Polysaccharide fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide fraction 3 g
Study: 20134405
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 g
Study: 12735487
Drug: Psychiatric drugs
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric drugs
Study: 8836789
Drug: Epirubicin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin therapy (50 mg diluted in 50 ml saline, installed weekly for 8 weeks)
Study: 8836789
Drug: Epirubicin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin therapy
Study: 6437365
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of fluphenazine decanoate every two weeks
Study: 6437365
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of fluphenazine decanoate every two weeks
Study: 30308558
Drug: Ocriplasmin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin (single intravitreal injection)
Study: 15719220
Drug: Ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.3 mg/kg)
Study: 26771268
Drug: Physiologic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic solution (control)
Study: 16043723
Drug: Subcutaneous lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous lispro (0.15 units/kg every 2 h)
Study: 16043723
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous regular insulin (0.1 unit x kg(‐1) x h(‐1); CIRI group)
Study: 12454764
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (12+/‐1 g day(‐1))
Study: 8721940
Drug: Ginseng 100
Normalized name: Ginseng 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng 100 mg
Study: 8721940
Drug: Ginseng 200
Normalized name: ginseng 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng 200 mg
Study: 11601954
Drug: Surgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatments
Study: 29883497
Drug: ramipril (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (maximum dose 10 mg depending on blood pressure) for 24±6 weeks
Study: 27998854
Drug: Early active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early active antihypertensive treatment with SBP control target of 130‐140 mm Hg
Study: 27998854
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive treatment with SBP control target of 170‐180 mm Hg
Study: 15341255
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice a day)
Study: 10365734
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol valerate combined with micronized progesterone
Study: 10365734
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol combined with micronized progesterone
Study: 7497717
Drug: General anesthesia/intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia/intravenous patient‐controlled analgesia (general anesthesia)
Study: 2042443
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg, b.i.d., for 60 days
Study: 31468528
Drug: Web-based Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based Acceptance and Commitment Therapy (ACT) program
Study: 30167045
Drug: 80mg/8ml intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg/8ml intravenous phloroglucinol
Study: 27393928
Drug: Adjunctive systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive systemic amoxicillin 500 mg plus metronidazole 400 mg (3×/day, 7 days)
Study: 27393928
Drug: Adjunctive systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive systemic amoxicillin plus metronidazole
Study: 24346594
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled beclomethasone (n = 86)
Study: 19878037
Drug: Nitric oxide-liberating
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide-liberating cream applied twice daily for 10 days
Study: 19878037
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 10 days
Study: 12912723
Drug: Argatroban (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (2 micro g/kg per minute, adjusted to maintain aPTT at 1.5 to 3 times baseline for 5 to 7 days)
Study: 26506138
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 2% topical solution BID
Study: 7645037
Drug: BT563 (murine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (murine IgG1 anti-IL-2R antibody)
Study: 25828172
Drug: Cognitive existential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive existential couple therapy (CECT)
Study: 23328270
Drug: EZG 200
Normalized name: EZG
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZG 200 mg + ethanol 1 g/kg
Study: 23328270
Drug: Ethanol 1
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 1 g/kg
Study: 23328270
Drug: EZG 200
Normalized name: EZG
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZG 200 mg
Study: 19447249
Drug: Sequential docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential docetaxel after anthracycline chemotherapy (FEC for four cycles followed by docetaxel 100 mg/m2 for four cycles)
Study: 19447249
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (sequential docetaxel)
Study: 14977675
Drug: Brace-only treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace-only treatment
Study: 11345223
Drug: Ritonavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (600 mg twice daily)
Study: 11345223
Drug: Indinavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (800 mg 3 times daily)
Study: 11345223
Drug: Ritonavir/saquinavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir/saquinavir (400 mg each twice daily)
Study: 11345223
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in PI treatment